In the summer of 2026, IMAX finds itself at a crossroads familiar to any enterprise that has learned to do more with less: its profits are growing faster than its revenues, a sign of operational discipline, yet also a quiet warning that efficiency alone cannot sustain a premium valuation indefinitely. Trading at nearly three times the industry's price-to-earnings multiple, the company's stock encodes a belief in a future that has not yet fully arrived. The question investors are sitting with is an ancient one — whether the price of hope is justified by the weight of evidence.